Publications

Zoughbi WAl, Kim D, Alperstein SAnn, Ohara K, Manohar J, Greco N, Khani F, Robinson BD, Rao RA, Elemento O et al..  2021.  Incorporating cytologic adequacy assessment into precision oncology workflow using telepathology: An institutional experience.. Cancer Cytopathol.

Beg S, Bareja R, Ohara K, Eng KWha, Wilkes DC, Pisapia DJ, Zoughbi WAl, Kudman S, Zhang W, Rao R et al..  2021.  Integration of whole-exome and anchored PCR-based next generation sequencing significantly increases detection of actionable alterations in precision oncology.. Transl Oncol. 14(1):100944.

Alsaleem MA, Ball G, Toss MS, Raafat S, Aleskandarany M, Joseph C, Ogden A, Bhattarai S, Rida PCG, Khani F et al..  2020.  A novel prognostic two-gene signature for triple negative breast cancer.. Mod Pathol.

Karass M, Bareja R, Shelkey E, Vlachostergios PJ, Robinson BD, Khani F, Mosquera JMiguel, Scherr DS, Sboner A, Tagawa ST et al..  2019.  Oncogenic Addiction to ERBB2 Signaling Predicts Response to Trastuzumab in Urothelial Cancer.. J Natl Compr Canc Netw. 17(3):194-200.

Brady NJ, Bagadion AM, Singh R, Conteduca V, Van Emmenis L, Arceci E, Pakula H, Carelli R, Khani F, Bakht M et al..  2021.  Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer.. Nat Commun. 12(1):3372.

Robinson BD, Vlachostergios PJ, Bhinder B, Liu W, Li K, Moss TJ, Bareja R, Park K, Tavassoli P, Cyrta J et al..  2019.  Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling.. Nat Commun. 10(1):2977.